Status:
NOT_YET_RECRUITING
Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF
Lead Sponsor:
Hitit University
Conditions:
Familial Mediterranean Fever
Intestinal Disease
Eligibility:
All Genders
18-55 years
Brief Summary
This study aims to investigate the intestinal mucosal expression of key inflammatory markers, namely Interleukin-1 (IL-1), Interleukin-18 (IL-18), and Caspase-1, in patients with Familial Mediterranea...
Detailed Description
Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent episodes of fever, serositis, and elevated acute-phase reactants. The underlying pathophysiology ...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Confirmed diagnosis of Familial Mediterranean Fever (FMF) according to Tel-Hashomer clinical criteria and/or MEFV gene mutation analysis (for FMF group)
- Undergoing routine endoscopy with mucosal biopsy sampling
- Availability of sufficient formalin-fixed paraffin-embedded (FFPE) tissue for immunohistochemical analysis
- For controls: absence of systemic inflammatory or autoimmune disease -
Exclusion
- History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- Current use of immunosuppressive therapy (excluding colchicine)
- Severe infection, active malignancy, or other systemic disease affecting intestinal mucosa
- Inadequate biopsy specimen quality for histopathological evaluation
- \-
Key Trial Info
Start Date :
July 10 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 19 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06981520
Start Date
July 10 2025
End Date
January 19 2026
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hitit University Erol Olçok Training and Research Hospital
Çorum, Turkey (Türkiye), 19040